Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies.
Steven Paul is our president and CEO, a member of the board of directors and a venture partner at Third Rock Ventures. Dr. Paul brings to Voyager more than 35 years of neuroscience expertise and an extensive track record in CNS drug discovery and development. As a venture partner at Third Rock, he helps lead the ideation and development of new companies, including Voyager. Before joining Voyager as president & CEO, Dr. Paul was the founding director of the Appel Alzheimer’s Disease Research Institute, where he was the principal investigator of the Institute’s novel adeno-associated virus (AAV) gene therapy program for Alzheimer’s disease, as well as professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. Preceding his appointment at Weill Cornell, Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including president of the Lilly Research Laboratories, and vice president of discovery research and neuroscience research. As president of the Lilly Research Laboratories, he was responsible for the company’s overall R&D strategy, expanding its efforts in oncology and biotechnology and resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Dr. Paul served as scientific director of the National Institute of Mental Health. He has also served as medical director in the Commissioned Corps of the United States Public Health Service. Dr. Paul has authored or co-authored more than 500 papers and book chapters. He is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Paul currently serves on the board of Sage Therapeutics and Alnylam Pharmaceuticals, and is a chairman of the board for the Foundation for the National Institutes of Health. He previously served on the board of the Sigma Aldrich company, which was acquired by Merck KGaA.
Dr. Paul holds a B.A. in biology and psychology from Tulane University and an M.S. and M.D. from the Tulane University School of Medicine.
Jane Pritchett Henderson is our senior vice president and chief financial officer. She has more than 28 years of life sciences industry and banking experience and leadership. Prior to Voyager, Ms. Henderson served as chief financial and business officer of Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc., in late 2016. Previously, Ms. Henderson served as vice president, business development of ISTA Pharmaceuticals, Inc., when ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson served as chief financial officer and head of business development at Axerion Pharmaceuticals, Inc., and as chief financial officer and chief business officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the Board of Directors of Eleven Biotherapeutics, Inc.
Ms. Henderson holds a B.S. in psychology from Duke University.
Bernard Ravina is our Chief Medical Officer. He brings deep expertise across a number of CNS diseases and more than 15 years of clinical research experience in both academia and industry. Prior to Voyager, Dr. Ravina was medical director in clinical development at Biogen Idec. There, he worked on both small molecule drugs and biologics for the treatment of neurological disorders and was responsible for biomarker and clinical development plans in Parkinson’s disease, stroke and neuropathic pain. Before joining Biogen Idec, Dr. Ravina was associate professor of neurology, director of the movement and inherited neurological disorders unit, and associate chair of neurology at the University of Rochester School of Medicine. He is the author of more than 100 scientific publications.
Dr. Ravina holds an M.D. from Johns Hopkins University School of Medicine and a master’s in clinical epidemiology and biostatistics from the University of Pennsylvania. He completed residency training in neurology and a fellowship in Parkinson’s disease and movement disorders at the University of Pennsylvania.
Dinah Sah is our Chief Scientific Officer. She has more than 20 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Sah has led multiple programs from early research through Phase 1 clinical trials, as well as discovering novel therapeutic targets and drug candidates that have advanced into clinical development. Before joining Voyager, Dr. Sah was at Alnylam Pharmaceuticals, where she was most recently vice president of research, providing scientific leadership and administrative oversight of discovery research and multiple research and development programs. At Alnylam, her leadership of several RNAi therapeutics R&D programs resulted in the landmark demonstration of human proof-of-mechanism for this novel class of drugs. Prior to Alnylam, Dr. Sah was associate director of research at Biogen, where she led neuroscience research and strategic planning for neurobiology, and before that, she headed neuroscience research at Signal Pharmaceuticals, where she also led multiple corporate partnerships and projects. Dr. Sah is an inventor on more than 25 patents, and her publications across diverse research areas include 18 articles in the New England Journal of Medicine, Nature Medicine, Nature Biotechnology, Nature Neuroscience, Nature Chemical Biology, Nature Reviews Drug Discovery, Molecular Therapeutics, Neuron, PNAS and EMBO Journal.
Dr. Sah received a B.S. in biology from the Massachusetts Institute of Technology, a Ph.D. in neurobiology from Harvard University and completed her postdoctoral training at Harvard Medical School.
John Connelly is our vice president of program and alliance management. Prior to Voyager, Mr. Connelly held positions of increasing responsibility at Genzyme Corporation, most recently as the head of program management for rare diseases. In this role, Mr. Connelly led and/or managed a portfolio of projects ranging from preclinical to Phase 3 programs utilizing a multitude of therapeutic modalities including gene therapy. He started his program management career supporting the AAV gene therapy activities at Genzyme and thus brings to Voyager more than15 years of experience managing gene therapy programs. Along with his leadership in program management, Mr. Connelly also played key roles in many of Genzyme’s strategic alliances.
Mr. Connelly holds a B.S. in biochemistry from the University of Vermont and an MBA from Suffolk University.
Kathleen Hayes is our vice president of human resources. She has more than 25 years of experience in human resource leadership. Prior to Voyager, Ms. Hayes was the vice president of human resources for Insulet Corporation, where she led global initiatives focused on leadership development, culture, core values, recruiting and operations. Prior to Insulet, she held senior human resources roles for Outcome Sciences, PerkinElmer and Viacell.
Ms. Hayes received her B.A. from the University of Massachusetts and her MBA from Boston University.
Robert Pietrusko is our senior vice president of regulatory affairs and quality assurance. He has three decades of experience in regulatory affairs and pharmaceutical drug development across a wide range of therapeutic categories, including CNS disorders and products governed by the Center for Biologics Evaluation and Research (CBER) of FDA. Dr. Pietrusko has directed the worldwide approval of more than 30 new products and new indications and is a recognized leader in the pharmaceutical industry having served as a BIO representative for PDUFA III and IV reauthorization negotiations with FDA. Before joining Voyager, Dr. Pietrusko was vice president of global regulatory affairs & quality and an executive officer at ViroPharma, Inc. where he played a key role in the company’s acquisition and regulatory approvals of Cinryze, a plasma-derived orphan drug product for the treatment and prevention of angioedema attacks. Before ViroPharma, Dr. Pietrusko was senior vice president of regulatory affairs at Millennium Pharmaceuticals, where he directed the strategy and accelerated approval of Velcade in the U.S. and in more than 90 countries worldwide, including the centralized procedure in the EU. Prior to Millennium, he was a vice president of regulatory affairs at SmithKline Beecham (now Glaxo SmithKline), where he led the submission and approval strategies for more than 30 NDAs, sNDAs, BLAs and MAAs in multiple therapeutics areas. Dr. Pietrusko is the author or co-author of 52 scientific publications.
Dr. Pietrusko holds a B.S. in biology and a Bachelor of Pharmacy degree from Rutgers University, and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science. He completed his residency training in hospital pharmacy at Thomas Jefferson University Hospital.